News – Page 3
-
NewsStudy explores nanoparticle approach to pharmaceutical wastewater pollution
Marine bacteria and cerium oxide nanoparticles could reduce pharmaceutical contaminants and toxicity in wastewater, report shows.
-
NewsAI to accelerate Novo Nordisk’s Parkinson’s cell therapy
Cellular Intelligence’s AI-native platform to compress traditional process development for the pluripotent stem cell-derived dopaminergic progenitor therapy.
-
NewsMHRA proposes modernisation of gene therapy products classification
UK medicines agency calls for a more technologically neutral approach to the current legal definitions of gene therapy medicinal products.
-
NewsFDA refines strategy with one-day inspectional assessment pilot
Initiative shown to enhance agency’s efficacy by increasing the number of facilities it can assess, without comprising regulatory rigour.
-
NewsNew OCABR vaccine guidelines to improve regulation efficiency
One new guideline relevant to mRNA vaccines produced with LNPs and two revised guidelines for vaccines to treat infectious diseases.
-
NewsAmgen invests additional $300m to strengthen biomanufacturing in Puerto Rico
Expansion brings firm’s total US manufacturing commitment over the last year to nearly $2 billion.
-
NewsNovartis to site seventh new facility in North Carolina
New active pharmaceutical ingredient (API) facility in Morrisville to enable end‑to‑end manufacturing in the US.
-
NewsFDA marks progress in implementing real-time clinical trials
Advances agency’s goal in facilitating continuous trials, aimed at accelerating promising therapies.
-
NewsBioplastic produced from hemp waste potential eco-alternative for packaging films
Plant-based biocomposites improved resource efficiency and added value from biomass waste, study shows.
-
NewsCPHI Americas 2026 returns to Philadelphia with AI, regulatory focus
The annual conference for contract pharmaceutical manufacturing partners returns to Pennsylvania, centering on regulatory shifts, AI and biotech innovation.
-
NewsBoehringer’s GLP-1 dual agonist survodutide shines in phase III trial
Survodutide could become first global glucagon/GLP-1 dual agonist, new phase III findings suggest.
-
NewsFDA approves Breztri as first triple-therapy inhaler for asthma
AstraZeneca’s Breztri Aerosphere has become the first fixed-dose triple-combination inhaler approved by the FDA for asthma maintenance treatment in adults and adolescents aged 12 and older, addressing unmet needs for approximately 13.5 million US patients uncontrolled on dual therapies.
-
NewsLilly adds potential first-in-class Type II JAK2 inhibitor to haematology portfolio
The pharmaceutical company’s $2.3 billion acquisition of Ajax Therapeutics set to advance outcomes for myeloproliferative neoplasms.
-
NewsOtarmeni Regeneron’s first genetic medicine to gain approval
Authorisation of the AAV gene therapy in the US marks a milestone for treating genetic hearing loss.
-
NewsNovel NMR-based method could facilitate safer API manufacturing
The innovative approach for detecting nitrosamine impurities in APIs addresses limitations of traditional mass-based techniques, research says.
-
NewsAmgen’s Chief Technology Officer Dr David Reese to retire
His two-decade tenure at the biopharmaceutical company has strengthened its aim for “convergent innovation” in medicine development.
-
NewsAbbVie expands US footprint with new $1.4 billion manufacturing campus
Small volume parenteral (SVP) manufacturing investment represents company’s largest capital investment to date.
-
NewsManufacturing data innovation set to accelerate medicine development
CMAC’s milestone aids the pharmaceutical industry’s transition from manual and siloed data operations to connected, intelligent manufacturing systems.
-
NewsDigital framework could optimise pharmaceutical wastewater treatment design
Combining machine learning and modelling has shown promise for supporting efficient tetracycline degradation and minimising electrical energy consumption in wastewater treatment.
-
NewsUCB expands into regenerative cell therapy through $1.15bn Neurona acquisition
Epilepsy-focused acquisition accelerates UCB’s entry into developing next generation disease-modifying therapies.